Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to $0.23.
- Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) rose 13000.0% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.56, marking a year-over-year increase of 47333.33%. This contributed to the annual value of $0.04 for FY2024, which is 10721.37% up from last year.
- According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) is $0.23, which was up 13000.0% from $0.16 recorded in Q2 2025.
- Aurinia Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $0.23 for Q3 2025, and its period low was -$0.4 during Q1 2021.
- Its 5-year average for EPS (Weighted Average and Diluted) is -$0.11, with a median of -$0.09 in 2023.
- As far as peak fluctuations go, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) plummeted by 7391.3% in 2021, and later soared by 150000.0% in 2025.
- Quarter analysis of 5 years shows Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.26 in 2021, then grew by 28.75% to -$0.18 in 2022, then decreased by 2.39% to -$0.19 in 2023, then soared by 105.36% to $0.01 in 2024, then soared by 2182.73% to $0.23 in 2025.
- Its last three reported values are $0.23 in Q3 2025, $0.16 for Q2 2025, and $0.16 during Q1 2025.